Azellon Cell Therapeutics Completes £650K

Azellon Cell Therapeutics Ltd, a London, UK-based developer of a stem cell therapy for the repair of torn meniscal cartilage, recently completed a £650k financing round.

The round was led by new investor Mr. Hugh Osmond, with participation from existing investors IP Group and Oxford Technology Management.

The company is using the capital to take its stem cell bandage, which has been designed as an alternative to surgical removal, into human clinical trials and for related commercial activities.
This Medicines and Healthcare products Regulatory Agency (MHRA) approved Phase I/IIa trial will treat 10 meniscal tear patients with a cell bandage product, seeded with the patient’s own stem cells. The trial will be undertaken at Southmead Hospital in Bristol and is scheduled to begin in May 2012 with interim data available within 18 months.

Co-founded by CSO Professor Anthony Hollander, Azellon is a spin-out company from the University of Bristol.



Join the discussion